Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II.

Lei, Chuqi; Kong, Xiangyi; Sullivan, Ryan J; Wu, Caisheng; Wang, Dawei; Zhang, Lin

Lei, Chuqi; Kong, Xiangyi; Sullivan, Ryan J; Wu, Caisheng; Wang, Dawei; Zhang, Lin.

Affiliation

Lei C; Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cance, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Kong X; Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cance, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Sullivan RJ; Department of Breast Surgical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Wu C; Center for Melanoma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University, Boston, MA, United States.
Wang D; Laboratory Animal Center, Xiamen University, Xiamen, China.
Zhang L; School of Pharmaceutical Sciences, Xiamen University, Xiamen, China.

Front Pharmacol ; 14: 1136373, 2023.

Article de En | MEDLINE | ID: mdl-36814493

Mots clés

PD-1/PD-L1 inhibitors; cancer; clinical features; immunotherapy; toxicity mechanism

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Front Pharmacol Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google